Hereditary nonpolyposis colorectal cancer (HNPCC)/lynch syndrome;Erblicher Darmkrebs ohne Polyposis

Deutsches Arzteblatt International

Volumn 110, Issue 3, 2013, Pages 32-38

  Steinke, Verena ^a   Engel, Christoph ^b   Büttner, Reinhard ^c   Schackert, Hans Konrad ^d   Schmiegel, Wolff H ^e   Propping, Peter ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b UNIVERSITY OF LEIPZIG   (Germany)

^c UNIVERSITY OF COLOGNE   (Germany)

^d UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^e RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER RISK; COLONOSCOPY; ENDOSCOPIC POLYPECTOMY; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; RISK REDUCTION; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; DIFFERENTIAL DIAGNOSIS; GENETIC COUNSELING; GENETIC MARKER; GENETIC PREDISPOSITION; GENETIC SCREENING; GENETICS; PROCEDURES; SINGLE NUCLEOTIDE POLYMORPHISM;

GENETIC MARKER;

COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; DIAGNOSIS, DIFFERENTIAL; GENETIC COUNSELING; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HUMANS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84906329091     PISSN: 18660452     EISSN: None     Source Type: Journal    
DOI: 10.3238/arztebl.2013.0032     Document Type: Article

References (24)

1. Rahner N, Steinke V: Hereditary cancer syndromes. Dtsch Arztebl Int 2008;105:706-14.
2. Lynch HT, Lynch JF: Hereditary nonpolyposis colorectal cancer (Lynch syndromes I and II): a common genotype linked to oncogenes? Med Hypotheses 1985;18:19-28.
3. Peltomaki P, Aaltonen LA, Sistonen P, et al.: Genetic mapping of a locus predisposing to human colorectal cancer. Science 1993;260:810-2.
4. Aaltonen LA, Peltomaki P, Leach FS, et al.: Clues to the pathogenesis of familial colorectal cancer. Science 1993;260:812-6.
5. Leach FS, Nicolaides NC, Papadopoulos N, et al.: Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer. Cell 1993;75:1215-25.
6. Vasen HF, Mecklin JP, Khan PM, Lynch HT: The International Collabora - tive Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC). Diseases of the Colon and Rectum 1991;34:424-5.
7. Vasen HF, Watson P, Mecklin JP, Lynch HT: New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) pro - posed by the International Collaborative group on HNPCC. Gastroenterology 1999;116:1453-6.
8. Umar A, Boland CR, Terdiman JP, et al.: Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 2004;96:261-8.
9. Rodriguez-Bigas MA, Boland CR, Hamilton SR, et al.: A National Cancer Institute Workshop on Hereditary Nonpolyposis Colorectal Cancer Syndrome: meeting highlights and Bethesda guidelines. J Natl Cancer Inst 1997;89:1758-62.
10. Lynch HT, Lynch PM, Lanspa SJ, Snyder CL, Lynch JF, Boland CR: Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications. Clin Genet 2009;76:1-18.
11. Lamberti C, Mangold E, Pagenstecher C, et al.: Frequency of hereditary non-polyposis colorectal cancer among unselected patients with colorectal cancer in Germany. Digestion 2006;74:58-67.
12. Watson P, Vasen HF, Mecklin JP, et al.: The risk of extra-colonic, extraendometrial cancer in the Lynch syndrome. Int J Cancer 2008;123:444-9.
13. Stoffel E, Mukherjee B, Raymond VM, et al.: Calculation of risk of colorectal and endometrial cancer among patients with Lynch syndrome. Gastroenterology 2009;137:1621-7.
14. Kastrinos F, Mukherjee B, Tayob N, et al.: Risk of pancreatic cancer in families with Lynch syndrome. JAMA 2009;302:1790-5.
15. Bonadona V, Bonaiti B, Olschwang S, et al.: Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA 2011;305:2304-10.
16. Engel C, Rahner N, Schulmann K, et al.: Efficacy of annual colonoscopic surveillance in individuals with hereditary nonpolyposis colorectal cancer. Clin Gastroenterol Hepatol 2010;8:174-82.
17. Moreira L, Balaguer F, Lindor N, et al.: Identification of Lynch Syndrome among patients with colorectal cancer. JAMA 2012;15:1555-65.
18. Vasen HF, Moslein G, Alonso A, et al.: Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer). J Med Genet 2007;44:353-62.
19. Järvinen HJ, Aarnio M, Mustonen H, et al.: Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 2000;118:829-34.
20. Järvinen HJ, Renkonen-Sinisalo L, Aktan-Collan K, Peltomaki P, Aaltonen LA, Mecklin JP: Ten years after mutation testing for Lynch syndrome: cancer incidence and outcome in mutation-positive and mutationnegative family members. J Clin Oncol 2009;27:4793-7.
21. Vasen HF, Abdirahman M, Brohet R, et al.: One to 2-year surveillance intervals reduce risk of colorectal cancer in families with Lynch syn - drome. Gastroenterology 2010;138:2300-6.
22. Ribic CM, Sargent DJ, Moore MJ, et al.: Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003;349:247-57.
23. Dove-Edwin I, Boks D, Goff S, et al.: The outcome of endometrial carcinoma surveillance by ultrasound scan in women at risk of hereditary nonpolyposis colorectal carcinoma and familial colorectal carcinoma. Cancer 2002;94:1708-12.
24. Renkonen-Sinisalo L, Sipponen P, Aarnio M, et al.: No support for endoscopic surveillance for gastric cancer in hereditary non-polyposis colorectal cancer. Scand J Gastroenterol 2002;37:574-7.